{"classes":[{"categories":[{"measurements":[{"comment":"No participants experienced an event and DOR was not reached.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"description":"Tumor assessment was performed using RECIST v1.1 criteria for participants with LGG. While the data for LGG in the phase II cohort is presented separately in other parts of the record, it was also considered useful to combine the data for LGG from phase I and phase II, which was done here.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with Low Grade Glioma","id":"OG000","title":"Low Grade Glioma"}],"paramType":"MEDIAN","populationDescription":"The safety evaluable population was defined as all participants who received at least one dose of study drug. Participants enrolled into phase I (Dose-Escalation) cohorts independent of their tumor type. For phase II, only one tumor type cohort was opened (LGG). As the same criteria were not used to assess response in all tumor types, the efficacy analyses were broken down by tumor type.","reportingStatus":"POSTED","timeFrame":"From first occurrence of objective response to disease progression or death due to any cause, whichever occurs first (up to 5 years, 2 months)","title":"Duration of Response (DOR) as Determined by the Investigator Using RECIST v1.1 for Participants With LGG (Phase I and II)","type":"SECONDARY","unitOfMeasure":"Months"}